Manoj Kumar Chhikara | Director, R&D
MSD Wellcome Trust Hilleman Laboratories | India

Manoj Kumar Chhikara, Director, R&D, MSD Wellcome Trust Hilleman Laboratories

Dr. Manoj Kumar, (Ph.D., Bacteriology) is working as Director, R&D heading the conjugate vaccine research at MSD Wellcome Trust Hilleman Laboratories in New Delhi. In his 15 years of research career, he has worked on different stages of development of several vaccine candidates, biosimilar products and diagnostics from concept till pre-clinical development and regulatory submissions. His major contributions come in research and development of multivalent pneumococcal, meningococcal and H. influenzae type b conjugate vaccines, acellular pertussis vaccine, monoplex and multiplexed immunoassays, multiplexed and quantitative PCRs, monoclonal antibodies against polysaccharides and protein antigens. He has participated in expert group meetings focused on pneumococcal vaccine and epidemiology conducted by WHO, ICMR and ASIP group. He is a contributing scientist for WHO TRS977 Annex 3 for recommendations to assure quality, safety and efficacy of pneumococcal conjugate vaccines and 3 WHO expert reports. He has 13 patent applications, 12 peer reviewed publications, 2 book chapters, 4 popular articles, several gene sequences, 12 national and international awards in his name. His focus areas include: New vaccine development; Cost effective vaccine technologies; Developing faster analytical methods, and Technology transfers.


Conference Day 1 @ 14:20

Sustainability of Vaccines Industry: Coping with pricing pressures

India is supplying more than 60% of the vaccines procured by GAVI. Vaccines in the public market are older and mass manufactured. Due to the cost of production, new vaccines are not able to enter the market. Should local vaccine manufacturers focus on ensuring cheap production of old vaccines for the public market or should they develop new vaccines for their private market instead? This session will explore differences between public & private markets, together with strategies for navigating the public market.
  • Comparing the differences between public and private market in terms of development and production cost
  • Understanding the differences in demands for both markets
  • What are some challenges that are unique to the public market? (E.g. Price pressures from GAVI, WHO)
  • Explore strategies in overcoming these challenges to achieve a sustainable model

Conference Day 1 @ 16:10

Synthetic conjugate vaccines: An overview

  •     Understanding the difference between traditional conjugate vaccines vs synthetic conjugate vaccines
  •     How do synthetic conjugates help in increasing product quality and reducing cost?
  •     Review of existing synthetic conjugate vaccines and ongoing research
  •     Presentation of preliminary data from MSD Wellcome Trust Hilleman Laboratories

back to speakers